Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof

A method for the treatment of a disease selected from the group consisting of heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension, and shock, comprising administering to said subject an effective amount of an angiotensin-receptor-agonist and/or a precursor thereof,

• wherein said subject has an amount of DPP3 protein and/or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

A method for prognosing the risk of an adverse event in said subject, wherein said method is comprising the steps:

• determining the level of DPP3 in a sample of bodily fluid of said subject;
• comparing said level of determined DPP3 to a predetermined threshold,
• correlating said level of DPP3 with said risk of an adverse event in said subject, wherein an elevated level above a certain threshold is predictive for an enhanced risk of said adverse events.

A method for prognosing the risk of an organ dysfunction in said subject, wherein said method is comprising the steps:

• determining the level of DPP3 in a sample of bodily fluid of said subject;
• comparing said level of determined DPP3 to a predetermined threshold,
• correlating said level of DPP3 with said risk of an adverse event in said subject, wherein an elevated level above a certain threshold is predictive for an enhanced risk of said adverse events.